DLA Piper has advised Kartos Therapeutics. Kartos Therapeutics, a US-based clinical stage biotechnology company, has entered into an agreement to be acquired by the French biopharmaceutical...
Ipsen Acquires Kartos Therapeutics in US$1.75 Billion Deal
Ascentage Pharma Raises US$192.3 Million in Offshore Share Placement
DLA Piper has advised Ascentage Pharma Group International. Ascentage Pharma Group International, a global biopharmaceutical company focused on addressing unmet medical needs in oncology, has completed...
Axsome Therapeutics Secures US$570 Million Financing and Equity Investment from Blackstone
DLA Piper provided counsel to Axsome Therapeutics, Inc. on the transaction. Axsome Therapeutics, Inc. has entered into a significant financial arrangement with Blackstone, comprising a US$570...
Iovance Biotherapeutics’ US$211 Million Common Stock Offering
DLA Piper advised Iovance Biotherapeutics, Latham & Watkins advised the underwriters on the transaction. Iovance Biotherapeutics, Inc. (Iovance), a biotechnology company focused on innovating, developing and...
Axsome Therapeutics’ US$225 Million Shares Public Offering
DLA Piper advised Axsome Therapeutics on the offering. Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics’ License Agreement with Pharmanovia
DLA Piper advised Axsome Therapeutics on the deal. Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Iovance Biotherapeutics’ $200 Million Acquisition of Proleukin
DLA Piper advised Iovance Biotherapeutics in the deal. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced its definitive agreement with Clinigen Limited to acquire Proleukin® (aldesleukin), an interleukin-2...
Axsome Therapeutics’ Acquisition of Sunosi
DLA Piper represented Axsome Therapeutics in the transaction. Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced...